Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 crossover study of ivacaftor and VX-661 + ivacaftor in cystic fibrosis with F508del and residual-function CFTR mutation
NL-OMON43608Phase 3Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivacaftor and tezacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change in percent predicted FEV1. Planned start Jun 2015; status: not yet recruiting.
02
Drugs
ivacaftortezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON43608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43608.